Benitec Biopharma: ASX Spotlight Series (Asia, Oct 2014)

Company Presentations

by Carolyn Herbert

Benitec Biopharma Limited (ASX:BLT) CEO & Managing Director Peter French presents at ASX Spotlight Series Asia.
 
The company’s presentation is titled, “Gene Silencing: A quiet revolution in healthcare”.
 
Mr French discusses Benitec Biopharma’s investment case, value proposition and recent highlights. 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.